Top Back to top

Evaluation of Outcomes following Allogeneic HCT in Pediatric Patients with High-Risk AML

Type d'étude:
Numéro de l'étude:
 
Type de traitement:
Allogeneic
Maladies:
Acute Myeloid Leukaemia (AML)
Titre court:
 
Objectif principal:
The primary end points are: overall survival
Secondary end points are: progression-free survival, non-relapse mortality, incidence of relapse
Principaux critères d'inclusion:
 
Pays:
 
Investigateur principal:
Akshay Sharma
Coordinateur EBMT de l'étude:
Arnaud Dalissier
E-mail du coordinateur de l'étude:
arnaud.dalissier@upmc.fr